ALPINE GROUP PARTNERS, LLC. lobbying for CARL ZEISS, INC.

Filing · LD-1 registration Registration

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 18, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

New York

Official filing document

Lobbyists on this filing 5

CURTIS PHILIP New on this filing

Previously held: Deputy Chief of Staff, Rep. Lamar Smith/Professional Staff member, House Science Cmte; Legislative Director, Rep. Louie Gohmert; Legislative Counsel, Rep. Bill Cassidy; Legislative Correspondent, Sen. Chuck Grassley
ERIN MENDELSOHN New on this filing

Previously held: LD, Rep. Anna Eshoo; Congressional Liaison - FDA
MICHAEL SEAN HAYWOOD New on this filing

Previously held: LA, Senator Jim Bunning; LA, Rep. Dave Camp
COLIN BRAINARD New on this filing

Previously held: Chief of Staff, Rep. Steve Watkins; Executive Director, Joint Economic Cmte.; Dep. Chief of Staff, Rep. Erik Paulsen; Dep. Chief of Staff, Rep. Lynn Jenkins; LC, Sen. Richard Burr
JENNIFER FORREST New on this filing

Previously held: Executive Asst. Rep. Greg Walden

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Lobbying activity 5

Science/Technology

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and Industrial Quality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Trade (domestic/foreign)

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and Industrial Quality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Manufacturing

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and Industrial Quality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Waste (hazardous/solid/interstate/nuclear)

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and Industrial Quality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Health Issues

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and Industrial Quality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

CARL ZEISS, INC.

Germany · Oberkochen 73447 · owns 100% of the client · contributed $0